NCT07306273

IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

A Single-Arm, Open-Label Clinical Study of Irreversible Electroporation(IRE) Combined With the Dual-Function Antibody PD-1/CTLA-4 (Apalulizumab) for the Treatment of Locally Advanced Pancreatic Cancer Following Failure of First-Line AG Therapy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study explores the efficacy and safety of irreversible electroporation(IRE) combined with the dual-function antibody PD-1/CTLA-4 (Apalulizumab) for the treatment of locally advanced pancreatic cancer following failure of first-line AG therapy. This research aims to accumulate more clinical evidence and treatment options for second-line therapy in locally advanced pancreatic cancer following failure of first-line regimen.

Conditions

• Pancreatic Adenocarcinoma Locally Advanced

Interventions

Type	Name	Description
RADIATION	Irreversible electroporation	Irreversible electroporation for pancreatic tumor
DRUG	Dual-Function Antibody PD-1/CTLA-4	Dual-Function Antibody PD-1/CTLA-4 iv. injection

Timeline

• Start date: 2025-12-15
• Primary completion: 2027-08-01
• Completion: 2027-08-01
• First posted: 2025-12-29
• Last updated: 2025-12-29

Locations

1 site across 1 country: China